Patients with some types of breast cancer will have a new clinical trial option at Fox Chase Cancer Center. Medical oncologists Lori Goldstein, MD, and Elias Obeid, MD, MPH, are opening a phase II immunotherapy clinical trial for newly diagnosed, locally recurrent, or metastatic HER2-overexpressing breast cancer.
The investigators are seeking to learn how the programmed cell death ligand 1 inhibitor atezolizumab (Tecentriq) works when used in combination with the standard-of-care regimen of -paclitaxel, pertuzumab (Perjeta), and trastuzumab (Herceptin). This clinical trial will study both the safety and efficacy of the drug combination in treating this type of breast cancer. Researchers on the team will also study biomarkers to learn more about how effective this combination will be at attacking the cancer on a molecular level.
Drs. Goldstein and Obeid are seeking 50 patients over the age of 18 who have locally recurrent, unresectable, or metastatic HER2-overexpressing breast cancer to participate in this study. Eligible patients may have received one prior hormonal treatment for metastatic disease. ■